{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T17:55:03Z","timestamp":1786384503805,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>The aim of this study was to analyse the predictive value of CTA-determined tricuspid annular dilatation (TAD) on the persistence of tricuspid regurgitation (TR) in patients undergoing transcatheter aortic valve replacement (TAVR) for severe aortic stenosis (AS) and concomitant at least moderate TR.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and results<\/jats:title>\n                <jats:p>288 consecutive patients treated with TAVR due to severe AS and concomitant at least moderate TR at baseline were included in the analysis. As cutoff for TAD, the median value of the CTA-determined, to the body surface area-normalized tricuspid annulus diameter (25.2\u00a0mm\/m<jats:sup>2<\/jats:sup>) was used. TAD had no impact on procedural characteristics or outcomes, including procedural death and technical or device failure according to the Valve Academic Research Consortium 3 criteria. However, the primary outcome of the study\u2014TR persistence after TAVR was significantly more frequent in patients with compared to patients without TAD (odds ratio 2.60, 95% confidence interval 1.33\u20135.16, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). Multivariable logistic regression analysis, adjusting for clinical and echocardiographic baseline characteristics, which are known to influence aetiology or severity of TR, confirmed TAD as an independent predictor of TR persistence after TAVR (adjusted odds ratio 2.30, 95% confidence interval 1.20\u20134.46, <jats:italic>p<\/jats:italic>\u2009=\u20090.01). Moreover, 2\u00a0year all-cause mortality was significantly higher in patients with persistence or without change of TR compared to patients with TR improvement (log-rank <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In patients undergoing TAVR for severe AS and concomitant at least moderate TR at baseline, TAD is a predictor of TR persistence, which is associated with increased 2-year all-cause mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00392-023-02152-0","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T15:04:09Z","timestamp":1673622249000},"page":"645-655","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["CTA-determined tricuspid annular dilatation is associated with persistence of tricuspid regurgitation after transcatheter aortic valve replacement"],"prefix":"10.1007","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6425-8946","authenticated-orcid":false,"given":"Kornelia","family":"L\u00f6w","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Steffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Theiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Orban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos D.","family":"Rizas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Haum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp M.","family":"Doldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Stolz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Gmeiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hagl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Massberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Hausleiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Deseive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"2152_CR1","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1093\/eurheartj\/ehx381","volume":"38","author":"P G\u00e9n\u00e9reux","year":"2017","unstructured":"G\u00e9n\u00e9reux P, Pibarot P, Redfors B et al (2017) Staging classification of aortic stenosis based on the extent of cardiac damage. Eur Heart J 38:3351\u20133358. https:\/\/doi.org\/10.1093\/eurheartj\/ehx381","journal-title":"Eur Heart J"},{"key":"2152_CR2","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jcmg.2018.09.027","volume":"12","author":"EA Prihadi","year":"2019","unstructured":"Prihadi EA, Delgado V, Leon MB et al (2019) Morphologic types of tricuspid regurgitation. JACC: Cardiovasc Imaging 12:491\u2013499. https:\/\/doi.org\/10.1016\/j.jcmg.2018.09.027","journal-title":"JACC: Cardiovasc Imaging"},{"key":"2152_CR3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","volume":"43","author":"A Vahanian","year":"2022","unstructured":"Vahanian A, Beyersdorf F, Praz F et al (2022) 2021 ESC\/EACTS guidelines for the management of valvular heart disease. Eur Heart J 43:561\u2013632. https:\/\/doi.org\/10.1093\/eurheartj\/ehab395","journal-title":"Eur Heart J"},{"key":"2152_CR4","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.jcin.2020.03.052","volume":"13","author":"F Khan","year":"2020","unstructured":"Khan F, Okuno T, Malebranche D et al (2020) Transcatheter aortic valve replacement in patients with multivalvular heart disease. JACC: Cardiovasc Interv 13:1503\u20131514. https:\/\/doi.org\/10.1016\/j.jcin.2020.03.052","journal-title":"JACC: Cardiovasc Interv"},{"key":"2152_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1161\/CIR.0000000000000923","volume":"2021","author":"CM Otto","year":"2020","unstructured":"Otto CM, Nishimura RA, Bonow RO et al (2020) ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines. Circulation 2021:143. https:\/\/doi.org\/10.1161\/CIR.0000000000000923","journal-title":"Circulation"},{"key":"2152_CR6","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1016\/j.jcin.2021.07.030","volume":"14","author":"D Tomii","year":"2021","unstructured":"Tomii D, Okuno T, Praz F et al (2021) Potential candidates for transcatheter tricuspid valve intervention after transcatheter aortic valve replacement. JACC: Cardiovasc Interv 14:2246\u20132256. https:\/\/doi.org\/10.1016\/j.jcin.2021.07.030","journal-title":"JACC: Cardiovasc Interv"},{"key":"2152_CR7","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.amjcard.2019.05.066","volume":"124","author":"J Yoshida","year":"2019","unstructured":"Yoshida J, Ikenaga H, Hayashi A et al (2019) Predictors and outcomes of persistent tricuspid regurgitation after transcatheter aortic valve implantation. Am J Cardiol 124:772\u2013780. https:\/\/doi.org\/10.1016\/j.amjcard.2019.05.066","journal-title":"Am J Cardiol"},{"key":"2152_CR8","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1016\/j.jcin.2020.06.027","volume":"13","author":"S Deseive","year":"2020","unstructured":"Deseive S, Steffen J, Beckmann M et al (2020) CT-determined tricuspid annular dilatation is associated with increased 2-year mortality in TAVR patients. JACC: Cardiovasc Interv 13:2497\u20132507. https:\/\/doi.org\/10.1016\/j.jcin.2020.06.027","journal-title":"JACC: Cardiovasc Interv"},{"key":"2152_CR9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.echo.2017.02.009","volume":"30","author":"H Baumgartner","year":"2017","unstructured":"Baumgartner H, Hung J, Bermejo J et al (2017) Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European association of cardiovascular imaging and the American society of echocardiography. J Am Soc Echocardiogr 30:372\u2013392. https:\/\/doi.org\/10.1016\/j.echo.2017.02.009","journal-title":"J Am Soc Echocardiogr"},{"key":"2152_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr 28:1-39.e14. https:\/\/doi.org\/10.1016\/j.echo.2014.10.003","journal-title":"J Am Soc Echocardiogr"},{"key":"2152_CR11","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1093\/ehjci\/jex139","volume":"18","author":"RT Hahn","year":"2017","unstructured":"Hahn RT, Zamorano JL (2017) The need for a new tricuspid regurgitation grading scheme. Eur Heart J Cardiovasc Imaging 18:1342\u20131343. https:\/\/doi.org\/10.1093\/ehjci\/jex139","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2152_CR12","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1016\/j.jacc.2021.02.038","volume":"77","author":"P G\u00e9n\u00e9reux","year":"2021","unstructured":"G\u00e9n\u00e9reux P, Piazza N, Alu MC et al (2021) Valve academic research consortium 3: updated endpoint definitions for aortic valve clinical research. J Am Coll Cardiol 77:2717\u20132746. https:\/\/doi.org\/10.1016\/j.jacc.2021.02.038","journal-title":"J Am Coll Cardiol"},{"key":"2152_CR13","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/ccd.27948","volume":"93","author":"H Takagi","year":"2019","unstructured":"Takagi H, Hari Y, Kawai N et al (2019) Impact of concurrent tricuspid regurgitation on mortality after transcatheter aortic-valve implantation. Catheter Cardiovasc Interv 93:946\u2013953. https:\/\/doi.org\/10.1002\/ccd.27948","journal-title":"Catheter Cardiovasc Interv"},{"key":"2152_CR14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/imi.0000000000000504","volume":"13","author":"B Worku","year":"2018","unstructured":"Worku B, Valovska M-T, Elmously A et al (2018) Predictors of persistent tricuspid regurgitation after transcatheter aortic valve replacement in patients with baseline tricuspid regurgitation. Innovations (Phila) 13:190\u2013199. https:\/\/doi.org\/10.1097\/imi.0000000000000504","journal-title":"Innovations (Phila)"},{"key":"2152_CR15","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMoa1814052","volume":"380","author":"MJ Mack","year":"2019","unstructured":"Mack MJ, Leon MB, Thourani VH et al (2019) Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 380:1695\u20131705. https:\/\/doi.org\/10.1056\/NEJMoa1814052","journal-title":"N Engl J Med"},{"key":"2152_CR16","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1056\/NEJMoa1816885","volume":"380","author":"JJ Popma","year":"2019","unstructured":"Popma JJ, Deeb GM, Yakubov SJ et al (2019) Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 380:1706\u20131715. https:\/\/doi.org\/10.1056\/NEJMoa1816885","journal-title":"N Engl J Med"},{"key":"2152_CR17","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1161\/CIRCULATIONAHA.121.057639","volume":"145","author":"M Banovic","year":"2022","unstructured":"Banovic M, Putnik S, Penicka M et al (2022) Aortic valve replacement versus conservative treatment in asymptomatic severe aortic stenosis: the AVATAR trial. Circulation 145:648\u2013658. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.057639","journal-title":"Circulation"},{"key":"2152_CR18","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1016\/j.jacc.2019.09.028","volume":"74","author":"M Taramasso","year":"2019","unstructured":"Taramasso M, Benfari G, van der Bijl P et al (2019) Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation. J Am Coll Cardiol 74:2998\u20133008. https:\/\/doi.org\/10.1016\/j.jacc.2019.09.028","journal-title":"J Am Coll Cardiol"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02152-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-023-02152-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02152-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T10:03:17Z","timestamp":1683194597000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-023-02152-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["2152"],"URL":"https:\/\/doi.org\/10.1007\/s00392-023-02152-0","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]},"assertion":[{"value":"21 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Simon Deseive and Julius Steffen received speaker honoraria from AstraZeneca. Daniel Braun and Christian Hagl received speaker honoraria from Abbott Vascular and Edwards Lifesciences. Martin Orban received speaker honoraria from Abbott Medical, AstraZeneca, Abiomed, Bayer vital, BIOTRONIK, Bristol-Myers Squibb, CytoSorbents, Daiichi Sankyo Deutschland, Edwards Lifesciences Services, and Sedana Medical. J\u00f6rg Hausleiter received research support and speaker honoraria from Abbott Vascular and Edwards Lifesciences. The other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}